Education
About Us
Working with TipRanks
Follow Us
Gyre Therapeutics (GYRE)
NASDAQ:GYRE
Total Valuation
Gyre Therapeutics has a market cap or net worth of $730.72M. The enterprise value is $588.42M.
Market Cap$730.72M
Enterprise Value$588.42M
Share Statistics
Gyre Therapeutics has 90,323,265 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding90,323,265
Owned by Insiders7.05%
Owned by Institutions0.02%
Financial Efficiency
Gyre Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 11.69%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)11.69%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee182.65K
Profits Per Employee30.91K
Employee Count579
Asset Turnover0.84
Inventory Turnover0.61
Valuation Ratios
The current PE Ratio of Gyre Therapeutics is 85.20. Gyre Therapeutics’s PEG ratio is -2.62.
PE Ratio85.20
PS Ratio0.00
PB Ratio-28.13
Price to Fair Value16.26
Price to FCF-16.01
Price to Operating Cash Flow-18.43
PEG Ratio-2.62
Income Statement
In the last 12 months, Gyre Therapeutics had revenue of 105.76M and earned 12.09M in profits. Earnings per share was 0.14.
Revenue105.76M
Gross Profit101.87M
Operating Income16.16M
Pretax Income23.22M
Net Income12.09M
EBITDA17.82M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was -6.65M and capital expenditures -2.21M, giving a free cash flow of -8.86M billion.
Operating Cash Flow-6.65M
Free Cash Flow-8.86M
Free Cash Flow per Share-0.10
Dividends & Yields
Gyre Therapeutics pays an annual dividend of $3.6, resulting in a dividend yield of ―
Dividend Per Share$3.6
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.27
52-Week Price Change-21.86%
50-Day Moving Average9.06
200-Day Moving Average11.22
Relative Strength Index (RSI)45.77
Average Volume (3m)306.15K
Important Dates
Gyre Therapeutics upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.
Last Earnings DateMay 9, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend DateJan 13, 2023
Financial Position
Gyre Therapeutics as a current ratio of 3.32, with Debt / Equity ratio of -0.18%
Current Ratio3.32
Quick Ratio2.99
Debt to Market Cap<0.01
Net Debt to EBITDA-0.57
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gyre Therapeutics has paid 5.32M in taxes.
Income Tax5.32M
Effective Tax Rate0.23
Enterprise Valuation
Gyre Therapeutics EV to EBITDA ratio is 57.22, with an EV/FCF ratio of -171.16.
EV to Sales9.64
EV to EBITDA57.22
EV to Free Cash Flow-171.16
EV to Operating Cash Flow-279.99
Balance Sheet
Gyre Therapeutics has $15.04M in cash and marketable securities with $1.58M in debt, giving a net cash position of -$13.46M billion.
Cash & Marketable Securities$15.04M
Total Debt$1.58M
Net Cash-$13.46M
Net Cash Per Share-$0.15
Tangible Book Value Per Share$1.15
Margins
Gross margin is -0.50%, with operating margin of 15.28%, and net profit margin of 11.43%.
Gross Margin-0.50%
Operating Margin15.28%
Pretax Margin21.95%
Net Profit Margin11.43%
EBITDA Margin16.85%
EBIT Margin15.35%
Analyst Forecast
The average price target for Gyre Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside152.10% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―